These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 11330956)

  • 1. Secondary cytoreductive surgery for localized intra-abdominal recurrences in epithelial ovarian cancer.
    Munkarah A; Levenback C; Wolf JK; Bodurka-Bevers D; Tortolero-Luna G; Morris RT; Gershenson DM
    Gynecol Oncol; 2001 May; 81(2):237-41. PubMed ID: 11330956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer.
    Santillan A; Karam AK; Li AJ; Giuntoli R; Gardner GJ; Cass I; Karlan BY; Bristow RE
    Gynecol Oncol; 2007 Mar; 104(3):686-90. PubMed ID: 17141302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [How to increase the optimal rate of secondary cytoreductive surgery in recurrent epithelial ovarian cancer].
    Li YF; Li MD; Liu FY; Liu JH; Li JD
    Ai Zheng; 2003 Nov; 22(11):1193-6. PubMed ID: 14613651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma.
    Tebes SJ; Sayer RA; Palmer JM; Tebes CC; Martino MA; Hoffman MS
    Gynecol Oncol; 2007 Sep; 106(3):482-7. PubMed ID: 17590420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of secondary cytoreductive surgery on survival of patients with advanced epithelial ovarian cancer.
    Zang RY; Zhang ZY; Li ZT; Cai SM; Tang MQ; Chen J; Liu Q
    Eur J Surg Oncol; 2000 Dec; 26(8):798-804. PubMed ID: 11087649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome.
    Salani R; Santillan A; Zahurak ML; Giuntoli RL; Gardner GJ; Armstrong DK; Bristow RE
    Cancer; 2007 Feb; 109(4):685-91. PubMed ID: 17219441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma.
    Chi DS; McCaughty K; Diaz JP; Huh J; Schwabenbauer S; Hummer AJ; Venkatraman ES; Aghajanian C; Sonoda Y; Abu-Rustum NR; Barakat RR
    Cancer; 2006 May; 106(9):1933-9. PubMed ID: 16572412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of secondary cytoreductive surgery for recurrent mucinous epithelial ovarian cancer (mEOC).
    Cheng X; Jiang R; Li ZT; Tang J; Cai SM; Zhang ZY; Tian WJ; Zang RY
    Eur J Surg Oncol; 2009 Oct; 35(10):1105-8. PubMed ID: 19443175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.
    Bristow RE; Montz FJ; Lagasse LD; Leuchter RS; Karlan BY
    Gynecol Oncol; 1999 Mar; 72(3):278-87. PubMed ID: 10053096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrent micropapillary serous ovarian carcinoma.
    Bristow RE; Gossett DR; Shook DR; Zahurak ML; Tomacruz RS; Armstrong DK; Montz FJ
    Cancer; 2002 Aug; 95(4):791-800. PubMed ID: 12209723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of salvage cytoreductive surgery in the treatment of patients with recurrent ovarian cancer after platinum-based chemotherapy.
    Matsumoto A; Higuchi T; Yura S; Mandai M; Kariya M; Takakura K; Fujii S
    J Obstet Gynaecol Res; 2006 Dec; 32(6):580-7. PubMed ID: 17100820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perioperative morbidity and outcome of secondary cytoreduction for recurrent epithelial ovarian cancer.
    Woelber L; Jung S; Eulenburg C; Mueller V; Schwarz J; Jaenicke F; Mahner S
    Eur J Surg Oncol; 2010 Jun; 36(6):583-8. PubMed ID: 20488646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beyond tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
    Shih KK; Chi DS; Barakat RR; Leitao MM
    Gynecol Oncol; 2010 Mar; 116(3):364-9. PubMed ID: 19897231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recurrent ovarian carcinoma of low malignant potential: the role of secondary surgical cytoreduction and the prognosis in Chinese patients.
    Zang RY; Yang WT; Shi DR; Xing Y; Cai SM
    J Surg Oncol; 2005 Jul; 91(1):67-72. PubMed ID: 15999350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Splenectomy during secondary cytoreduction for ovarian cancer disease recurrence: surgical and survival data.
    Manci N; Bellati F; Muzii L; Calcagno M; Alon SA; Pernice M; Angioli R; Panici PB
    Ann Surg Oncol; 2006 Dec; 13(12):1717-23. PubMed ID: 16957965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma.
    Scarabelli C; Gallo A; Carbone A
    Gynecol Oncol; 2001 Dec; 83(3):504-12. PubMed ID: 11733963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The benefits of low anterior en bloc resection as part of cytoreductive surgery for advanced primary and recurrent epithelial ovarian cancer patients outweigh morbidity concerns.
    Park JY; Seo SS; Kang S; Lee KB; Lim SY; Choi HS; Park SY
    Gynecol Oncol; 2006 Dec; 103(3):977-84. PubMed ID: 16837030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surgery in recurrent epithelial ovarian cancer: benefits on Survival for patients with residual disease of 0.1-1 cm after secondary cytoreduction.
    Tian WJ; Jiang R; Cheng X; Tang J; Xing Y; Zang RY
    J Surg Oncol; 2010 Mar; 101(3):244-50. PubMed ID: 20112269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tertiary cytoreduction in patients with recurrent ovarian carcinoma.
    Leitao MM; Kardos S; Barakat RR; Chi DS
    Gynecol Oncol; 2004 Oct; 95(1):181-8. PubMed ID: 15385129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits?
    Zang RY; Li ZT; Tang J; Cheng X; Cai SM; Zhang ZY; Teng NN
    Cancer; 2004 Mar; 100(6):1152-61. PubMed ID: 15022281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.